Earnings PerformanceFY24 results are at the top end of guidance with 7.7% organic revenue growth, the best since IPO.
Growth ProspectsConvatec's mid-term growth and margin expansion targets remain on track, reinforcing confidence in the company's growth prospects.
Regulatory ClarityThe postponement of the LCDs by the CMS removes uncertainty regarding the potential impact on InnovaMatrix, alleviating market concerns.